Posted by Michael Wonder on 09 Mar 2021
Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy designation for RP-L201 gene therapy for leukocyte adhesion deficiency-I
9 March 2021 - Enrollment complete in Phase 1/2 clinical trial of RP-L201 for the treatment of LAD-I.
Rocket Pharmaceuticals today announces that the U.S. FDA has granted regenerative medicine advanced therapy designation to RP-L201, its investigational gene therapy for the treatment of leukocyte adhesion deficiency-I.
The designation was granted based on encouraging preliminary safety and efficacy data from the ongoing Phase 1/2 clinical trial of RP-L201.
